Opus Genetics (IRD) closed at $4.23 on November 10, 2026, up 0.7% from the previous close, on volume of 1,031,335 shares (30-day average 1,439,814).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Opus Genetics GAAP EPS of -$0.46 misses by $0.31, revenue of $1.14M misses by $0.94M
Seeking Alpha News (Tue, 10-Nov 7:05 AM ET)
Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Mon, 2-Nov 4:39 PM ET)
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Globe Newswire (Wed, 21-Oct 7:00 AM ET)
Globe Newswire (Fri, 16-Oct 12:00 PM ET)
Globe Newswire (Thu, 15-Oct 4:00 PM ET)
Opus Genetics to Present at the Chardan Annual Healthcare Conference
Globe Newswire (Tue, 13-Oct 7:00 AM ET)
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Opus Genetics trades on the NASDAQ stock market under the symbol IRD.
As of November 10, 2026, IRD stock price climbed to $4.23 with 1,031,335 million shares trading.
IRD has a beta of 0.30, meaning it tends to be less sensitive to market movements. IRD has a correlation of 0.00 to the broad based SPY ETF.
IRD has a market cap of $351.92 million. This is considered a Small Cap stock.
Last quarter Opus Genetics reported $755,000 in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.02.
The top ETF exchange traded funds that IRD belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
IRD has outperformed the market in the last year with a price return of +111.5% while the SPY ETF gained +12.9%. IRD has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +15.6% and +27.4%, respectively, while the SPY returned -2.8% and -2.0%, respectively.
IRD support price is $3.97 and resistance is $4.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRD shares will trade within this expected range on the day.
